Market Intelligence, Clinical Progress, and High-Purity Reagents for Proliferation Marker Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KI67 drug discovery and diagnostic validation. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KI67 Recombinant Protein (FHA Domain / Functional Fragments) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 or E. coli expressed. |
View MKI67 Products |
| Gene Delivery | KI67 Promise-ORF / Lentivirus Full-length ORF or target fragments for expression and localization studies. |
View MKI67 Products |
| Benchmark Ab | Anti-KI67 Recombinant Antibody (Sequence of MIB-1) Recombinant positive control for IHC, Flow Cytometry, and ELISA. |
View MKI67 Products |
| Validator | KI67 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View MKI67 Products |
| Related Target A | PCNA Proinflammatory and proliferation-associated nuclear antigen; synergistic marker for cell cycle progression. |
View PCNA Products |
| Related Target B | MCM2 Minichromosome maintenance protein 2; essential for DNA replication initiation, highly correlated with KI67 index. |
View MCM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear localization & complex conformation | Domain-specific recombinant fragments (e.g., FHA domain) optimized for structural stability and binding assays. |
| High background in diagnostic assays | Recombinant Benchmark Antibodies (MIB-1 sequence) strictly verified for sequence accuracy to ensure reproducible positive controls. |
| Lack of physiological controls | Sequence-verified siRNA sets included for precise target knockdown and specificity validation. |
| Batch-to-batch variation in antigen quality | High purity (>95%) and endotoxin-controlled formulations with theoretical molecular weight verification. |
Live KI67 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of KI67 (MKI67) is expanding rapidly. Long established as the gold-standard prognostic biomarker (KI67 labeling index) in breast cancer, prostate cancer, and neuroendocrine tumors, modern drug discovery is now pivoting toward KI67 as a direct therapeutic target. The race for KI67 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to novel modalities such as antisense oligonucleotides (ASOs), siRNA-mediated knockdown, and small-molecule inhibitors targeting the KI67-PP1 (Protein Phosphatase 1) interaction interface. As first-generation therapies enter preclinical and early clinical validation, the next wave of R&D is targeting precise intracellular delivery systems and combination regimens to overcome cell-cycle-dependent drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptide | Academic Institutions, Biotech Startups | Solid Tumors, Breast Cancer | Protein-Protein Interaction (PPI) Assay (Need high-purity FHA domain and PP1-binding fragments) |
| siRNA / ASO | Oligonucleotide Therapeutics Developers | Refractory Cancers, Hyperproliferative Disorders | Target Knockdown Verification (Need sequence-verified siRNA sets and Lentiviral delivery) |
| Diagnostic Antibody (IVD) | Global Diagnostic Corporates (Roche, Agilent) | Oncology Companion Diagnostics (CDx) | Epitope Mapping & Cross-reactivity (Need high-purity antigen and recombinant benchmark antibodies) |